Research-backed articles covering peptide sourcing, lab test analysis, shop reviews, regulatory updates, and dosing guides. Written by the Peptigrity team. No sponsored content, no paid placements — every article is independent editorial.
Yes. Tirzepatide is FDA-approved on prescription as Mounjaro and Zepbound. The shortage-era compounding route closed in early 2025, it is on no FDA Category 2 list, and it is not on WADA's 2026 Prohibited List.
Yes. Tesamorelin is FDA-approved as Egrifta for one indication, can be compounded for a named patient, is on no FDA Category 2 list, and is prohibited at all times by WADA under…
Buyer Education & Quality VerificationNo marketed FDA-approved sermorelin exists: both Geref approvals were withdrawn in 2009, not for safety reasons. Pharmacies can compound it on prescription, and WADA prohibits it…